請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4422完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 賴美淑(Mei-Shu Lai) | |
| dc.contributor.author | Yi-Chun Yeh | en |
| dc.contributor.author | 葉怡君 | zh_TW |
| dc.date.accessioned | 2021-05-14T17:42:10Z | - |
| dc.date.available | 2018-07-01 | |
| dc.date.available | 2021-05-14T17:42:10Z | - |
| dc.date.copyright | 2015-09-14 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-08-19 | |
| dc.identifier.citation | 1. Liaw, Y.-F. and C.-M. Chu, Hepatitis B virus infection. The Lancet, 2009. 373(9663): p. 582-592.
2. Lu, S.N., et al., Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer, 2006. 119(8): p. 1946-52. 3. Chen, D.S., et al., A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. Jama, 1987. 257(19): p. 2597-603. 4. Ministry of health and welfare, Causes of death in Taiwan, 2012. 2012, Ministry of health and welfare: Taiwan. 5. Chang, M.-H., et al., Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children. New England Journal of Medicine, 1997. 336(26): p. 1855-1859. 6. Kao, J.H. and D.S. Chen, Global control of hepatitis B virus infection. Lancet Infect Dis, 2002. 2(7): p. 395-403. 7. Mazzaferro, V., et al., Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology, 2006. 44(6): p. 1543-1554. 8. Poon, R., Differentiating Early and Late Recurrences After Resection of HCC in Cirrhotic Patients: Implications on Surveillance, Prevention, and Treatment Strategies. Annals of Surgical Oncology, 2009. 16(4): p. 792-794. 9. Omata, M., et al., Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatology International, 2010. 4(2): p. 439-474. 10. Lin, S.-M., et al., Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2007. 46(1): p. 45-52. 11. Yuen, M.F., et al., Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology, 2001. 34(1): p. 139-45. 12. Papatheodoridis, G.V., E. Manesis, and S.J. Hadziyannis, The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology, 2001. 34(2): p. 306-313. 13. Yoshida, H., et al., Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatology International, 2008. 2(1): p. 89-94. 14. Kuzuya, T., et al., Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 2007. 22(11): p. 1929-1935. 15. Piao, C.Y., et al., Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. Acta medica Okayama, 2005. 59(5): p. 217-224. 16. Kubo, S., et al., Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatology Research, 2007. 37(2): p. 94-100. 17. Chan, A.C.Y., et al., Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus-Related Hepatocellular Carcinoma. Archives of Surgery, 2011. 146(6): p. 675-681. 18. McMahon, B.J., The natural history of chronic hepatitis B virus infection. Hepatology, 2009. 49(5 Suppl): p. S45-55. 19. Merican, I., et al., Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol, 2000. 15(12): p. 1356-61. 20. Fattovich, G., et al., Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology, 1997. 26(5): p. 1338-42. 21. Ikeda, K., et al., Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer, 1998. 82(5): p. 827-35. 22. Benvegnù, L., et al., Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer, 1998. 83(5): p. 901-909. 23. Brunetto, M.R., et al., Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. The Lancet, 1998. 351(9115): p. 1535-1539. 24. Krogsgaard, K., G. the Long-term Follow-up Investigator, and T. Executive Team on Anti-Viral, The long-term effect of treatment with interferon-α2a in chronic hepatitis B. Journal of Viral Hepatitis, 1998. 5(6): p. 389-397. 25. Di Marco, V., et al., The long-term course of chronic hepatitis B. Hepatology, 1999. 30(1): p. 257-264. 26. Mazzella, G., et al., Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol, 1999. 94(8): p. 2246-2250. 27. Lin, S.M., et al., Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology, 1999. 29(3): p. 971-5. 28. Tangkijvanich, P., et al., Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health, 2001. 32(3): p. 452-8. 29. Truong, B.X., et al., Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med, 2005. 16(2): p. 279-84. 30. Liaw, Y.-F., et al., Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. New England Journal of Medicine, 2004. 351(15): p. 1521-1531. 31. Matsumoto, A., et al., Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res, 2005. 32(3): p. 173-84. 32. Papatheodoridis, G.V., et al., Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology, 2005. 42(1): p. 121-9. 33. Yuen, M.F., et al., Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther, 2007. 12(8): p. 1295-303. 34. Eun, J.R., et al., Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. Journal of Hepatology, 2010. 53(1): p. 118-125. 35. Hosaka, T., et al., Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology, 2013. 58(1): p. 98-107. 36. Wong, G.L., et al., Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology, 2013. 58(5): p. 1537-47. 37. Llovet, J.M., A. Burroughs, and J. Bruix, Hepatocellular carcinoma. The Lancet, 2003. 362(9399): p. 1907-1917. 38. Llovet, J.M., Updated treatment approach to hepatocellular carcinoma. Journal of Gastroenterology, 2005. 40(3): p. 225-235. 39. Germani, G., et al., Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. Journal of Hepatology, 2010. 52(3): p. 380-388. 40. Schwartz, J.D., et al., Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. The Lancet Oncology, 2002. 3(10): p. 593-603. 41. Poon, R.T.P., Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology, 2011. 54(3): p. 757-759. 42. Shen, Y.-C., et al., Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology, 2010. 52(6): p. 889-894. 43. Sun, H.-C., et al., Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. Journal of Cancer Research and Clinical Oncology, 2006. 132(7): p. 458-465. 44. Chen, L.T., et al., Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection. Annals of Surgery, 2011. 255(1): p. 8-17. 45. Lo, C.M., et al., A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg, 2007. 245(6): p. 831-42. 46. Kao, J.-H. and D.-S. Chen, Global control of hepatitis B virus infection. The Lancet Infectious Diseases, 2002. 2(7): p. 395-403. 47. Li, N., et al., A Comparative Study of Antiviral Therapy After Resection of Hepatocellular Carcinoma in the Immune-Active Phase of Hepatitis B Virus Infection. Annals of Surgical Oncology, 2010. 17(1): p. 179-185. 48. Hung, I.F.N., et al., Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. American Journal of Gastroenterology, 2008. 103(7): p. 1663-1673. 49. Wu, C.-Y., et al., Association between nucleoside analogues and risk of hepatitis b virus–related hepatocellular carcinoma recurrence following liver resection. JAMA, 2012. 308(18): p. 1906-1913. 50. Hsu, C., Antiviral therapy and hepatitis b virus–related hepatocellular carcinoma recurrence. JAMA, 2013. 309(8): p. 765-765. 51. Yeh, Y.C., P.J. Chen, and M.S. Lai, Antiviral therapy and hepatitis b virus–related hepatocellular carcinoma recurrence. JAMA, 2013. 309(8): p. 765-767. 52. Cox, E., et al., Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health, 2009. 12(8): p. 1053-61. 53. Berger, M.L., et al., Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. Value Health, 2009. 12(8): p. 1044-52. 54. Schneeweiss, S., A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf, 2010. 19(8): p. 858-68. 55. Austin, P.C., An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behavioral Research, 2011. 46(3): p. 399-424. 56. Lévesque, L.E., et al., Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ, 2010. 340. 57. Suissa, S., Immortal time bias in observational studies of drug effects. Pharmacoepidemiology and Drug Safety, 2007. 16(3): p. 241-249. 58. Zhou, Z., et al., Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol, 2005. 162(10): p. 1016-23. 59. Howe, C.J., et al., Limitation of Inverse Probability-of-Censoring Weights in Estimating Survival in the Presence of Strong Selection Bias. American Journal of Epidemiology, 2011. 60. Schneeweiss, S., Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf, 2006. 15(5): p. 291-303. 61. Universal Health Coverage in Taiwan. 2011 May 2012 [cited 2012; Available from: http://www.nhi.gov.tw/Resource/webdata/21717_1_20120808UniversalHealthCoverage.pdf. 62. Taiwan Cancer Registry. Taiwan Cancer Registry. n.d. [cited 2012 5, April]; Bureau of Health Promotion, Department of Health, Taiwan, ROC:[Available from: http://tcr.cph.ntu.edu.tw/main.php?Page=N1. 63. Asrani, S.K., et al., Underestimation of Liver-Related Mortality in the United States. Gastroenterology, 2013. 145(2): p. 375-382.e2. 64. Quan, H., et al., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care, 2005. 43(11): p. 1130-9. 65. Cole, S.R. and M.A. Hernán, Adjusted survival curves with inverse probability weights. Computer Methods and Programs in Biomedicine, 2004. 75(1): p. 45-49. 66. Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med, 2009. 28(25): p. 3083-107. 67. Williamson, E.J., A. Forbes, and I.R. White, Variance reduction in randomised trials by inverse probability weighting using the propensity score. Statistics in Medicine, 2014. 33(5): p. 721-737. 68. Sato, T. and Y. Matsuyama, Marginal structural models as a tool for standardization. Epidemiology, 2003. 14(6): p. 680-6. 69. Chiang, C.J., et al., Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol, 2015. 45(3): p. 291-6. 70. Greene, F.L., et al., Liver including intrahepatic bile ducts, in AJCC Cancer Staging Handbook. 2002, Springer: New York. p. 131-144. 71. Wu, J.C., et al., Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol, 2009. 51(5): p. 890-7. 72. Hepatitis B and C Treatments. 2015 [cited 2015 June 10]; Available from: http://www.fda.gov/forpatients/illness/hepatitisbc/ucm408658.htm. 73. Sung, J.J., et al., Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther, 2008. 28(9): p. 1067-77. 74. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012. 57(1): p. 167-85. 75. Chen, C.J., et al., Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama, 2006. 295(1): p. 65-73. 76. Taiwan Cancer Registry Database 2005-2007. 2010, Taiwan Cancer Registry, Bureau of National Health Insurance, Department of Health: Taipei. p. 105. 77. Imamura, H., et al., Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol, 2003. 38(2): p. 200-7. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4422 | - |
| dc.description.abstract | 研究背景與目的：
B型肝炎是常見的傳染性疾病，許多末期肝病(如：肝硬化、肝癌)的發生與肝癌復發，皆與B型肝炎感染有關。因此，B型肝炎防治計畫，除了藉由疫苗防治控制B型肝炎感染外，必須透過更積極抗病毒藥品治療，控制B型肝炎病毒，舒緩肝臟發炎狀況，以期望延緩或降低肝硬化與肝癌的發生與復發。雖然過去研究業已指出抗病毒藥品降低肝硬化與肝癌發生與復發的療效，然而受限於研究樣本數，結果未有一致性。因此，本研究將評估 (1) 慢性B型肝炎病人，接受有治療期限規定之lamivudine、interferon或peg-interferon治療的長期療效，以及 (2) B型肝炎相關肝癌且接受治癒性肝癌治療病患，後續接受輔助性抗病毒治療的長期療效。 研究材料與方法： 本研究利用全民健康保險資料庫(National Health Insurance, NHI)與癌症登記資料庫(Taiwan Cancer Registry, TCR)建立世代研究，選取研究2004至2010年間，診斷為慢性B型肝炎病人，與新診斷並接受治癒性肝癌治療之B型肝炎相關肝癌病人，為研究對象。利用治療機率倒數加權(Inverse probability of treatment weighting, IPTW)以及傾向分數配對(Propensity score matching)進行校正，以Cox 比例風險模式(Cox proportional hazard model)，估計研究事件之風險比(Hazard ratios, HRs)與95%信賴區間(confidence intervals, CIs)。 研究結果： 於慢性B型肝炎病患研究中，相較於未治療組，有治療期限規定下lamivudine能有效降低肝癌 (HR, 0.46; 95%CI, 0.41-0.51)、肝臟相關疾病死亡(HR,0.68; 95%CI, 0.61-0.77)，以及全死因死亡(HR, 0.70; 95%CI, 0.64-0.76)的發生。此療效於有治療期限規定之interferon治療亦可發現相似的結果(肝癌：HR, 0.22; 95%CI, 0.15-0.31；肝臟相關疾病死亡：HR, 0.14; 95%CI, 0.07-0.27；全死因死亡：HR, 0.10; 95%CI, 0.06-0.18)。 於B型肝炎相關肝癌且接受治癒性肝癌治療病患研究中，接受輔助性抗病毒治療的病患，相較於未治療組，有較高風險的肝癌復發 (HR, 1.19; 95%CI, 1.03-1.37)，以及全死因死亡(HR, 1.22; 95%CI, 0.98-1.51)的發生。於治癒性肝癌治療後，不同時間點接受輔助性抗病毒治療，與肝癌復發及全死因死亡發生無顯著性相關。 結論： 本研究證實有治療期限規定之lamivudine, interferon與peg-interferon抗B型肝炎病毒藥品，用於治療慢性B型肝炎病患，可有效降低肝癌與死亡發生。然而，將抗B型肝炎病毒藥品，用於輔助治療B型肝炎相關肝癌且接受治癒性肝癌治療病患，則未觀察到其降低肝癌復發與死亡發生之療效。 | zh_TW |
| dc.description.abstract | BACKGROUND AND OBJECTIVE:
Hepatitis B virus (HBV) is one of high prevalence and serious global health problem. The end-stage liver diseases incidence and hepatocellular carcinoma (HCC) incidence or recurrence may be attributed to viral hepatitis B. Therefore, HBV control programs must be augmented by active antiviral treatment among patients with chronic hepatitis B (CHB) or HBV-related HCC. The efficacy of anti-HBV treatments in mitigating the incidence or recurrence of HCC and mortality has not yet been substantiated. This study was (1) to evaluate the effects of finite-period lamivudine (LAM) and interferon (IFN) or peg-interferon (PEG-IFN) treatments on HCC development and mortality among CHB patients, as well as (2) to investigate the effect of adjuvant antiviral therapies on HCC progression and deaths in HBV-related HCC patients following curative treatment. MATERIALS AND METHODS: A nationwide inception cohorts of CHB patients and newly diagnosed HBV-related HCC patients who received curative HCC therapy as the first course of treatment for the years 2004 to 2010 were identified from the National Health Insurance (NHI) program and the Taiwan Cancer Registry (TCR), respectively. This study employed a Cox proportional hazards model based on inverse probability of treatment weighting (IPTW) and propensity score matching to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: CHB patients who underwent finite-period lamivudine treatment presented greater reductions in HCC incidence (HR, 0.46; 95%CI, 0.41-0.51), liver-related mortality (HR, 0.68; 95%CI, 0.61-0.77), and all-cause mortality (HR, 0.70; 95%CI, 0.64-0.76) than patients in the untreated group. Finite-period interferon or peg-interferon therapy resulted in similar reductions in HCC incidence (HR, 0.22; 95%CI, 0.15-0.31), liver-related mortality (HR, 0.14; 95%CI, 0.07-0.27), and all-cause mortality (HR, 0.10; 95%CI, 0.06-0.18). HBV-related HCC patients following curative therapy who underwent adjuvant antiviral therapy demonstrated a higher risk of HCC progression (HR, 1.19; 95%CI, 1.03-1.37) and death from all causes (HR, 1.22; 95%CI, 0.98-1.51) than untreated patients. The interval length between initiation of antiviral therapy and first-line curative treatment did not show a significant association with HCC progression and all-cause mortality. CONCLUSIONS: Our results demonstrate the effectiveness of finite-period lamivudine, interferon, or peg-interferon anti-HBV therapy in reducing the incidence of HCC and mortality in the long-term follow-up of a large CHB patient population. However, this effect did not be found in reducing the risk of HCC progression or mortality in HBV-related HCC patients after curative therapy. | en |
| dc.description.provenance | Made available in DSpace on 2021-05-14T17:42:10Z (GMT). No. of bitstreams: 1 ntu-104-D00849007-1.pdf: 4617660 bytes, checksum: 3d62577e6037420e98339203d7cb3451 (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 摘要 I
ABSTRACT III CONTENTS V CONTENTS OF TABLES VII CONTENTS OF FIGURES IX CHAPTER 1 BACKGROUND 1 CHAPTER 2 LITERATURE REVIEW 3 2.1 Natural history of chronic hepatitis B 3 2.2 Antiviral therapies to prevent occurrence of hepatocellular carcinoma 6 2.2.1 Evolution of anti-HBV therapies 6 2.2.2 Specific intervention 8 2.2.3 Reimbursement under the Taiwan National Health Insurance program for antiviral therapy for hepatitis B virus 11 2.3 Adjuvant antiviral therapy to prevent recurrence of hepatocellular carcinoma 12 2.4 Biases in retrospective cohort studies based on secondary databases 14 2.5 Summary 18 CHAPTER 3 STUDY AIM AND FRAMEWORK 20 3.1 Study aim 20 3.2 Study framework 20 CHAPTER 4 MATERIALS AND METHODS 22 4.1 Effectiveness research of lamivudine or interferon/peginterferon in chronic hepatitis B patients 22 4.2 Effectiveness research of adjuvant antiviral therapy in hepatitis B virus-related hepatocellular carcinoma patients following curative treatment 28 CHAPTER 5 RESULTS 35 5.1 Effectiveness research of lamivudine or interferon/peginterferon in Chronic Hepatitis B patients 35 5.2 Effectiveness research of adjuvant antiviral therapy in hepatitis B virus-related hepatocellular carcinoma patients following curative treatment 59 CHAPTER 6 DISCUSSIONS 71 6.1 Effectiveness research of lamivudine or interferon/peginterferon in Chronic Hepatitis B patients 71 6.2 Effectiveness research of adjuvant antiviral therapy in hepatitis B virus-related hepatocellular carcinoma patients following curative treatment 75 6.3 Strengths and limitations 82 CHAPTER 7 CONCLUSION 86 REFERENCE 87 SUPPLEMENTARY 92 | |
| dc.language.iso | en | |
| dc.subject | 死亡 | zh_TW |
| dc.subject | 慢性B型肝炎 | zh_TW |
| dc.subject | B型肝炎相關肝癌 | zh_TW |
| dc.subject | 抗病毒治療 | zh_TW |
| dc.subject | 肝癌 | zh_TW |
| dc.subject | Hepatitis B Virus-related Hepatocellular carcinoma | en |
| dc.subject | Mortality | en |
| dc.subject | Hepatocellular carcinoma | en |
| dc.subject | Antiviral therapy | en |
| dc.subject | Chronic hepatitis B | en |
| dc.title | 抗B型肝炎病毒藥物治療之長期療效評估 | zh_TW |
| dc.title | Long-Term Effectiveness of Antiviral Therapy for Patients with Chronic Hepatitis B | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 陳培哲(Pei-Jer Chen),劉俊人(Chun-Jen Liu),陳建煒(Kin-Wei Chan),李文宗(Wen-Chung Lee),杜裕康(Yu-Kang Tu) | |
| dc.subject.keyword | 慢性B型肝炎,B型肝炎相關肝癌,抗病毒治療,肝癌,死亡, | zh_TW |
| dc.subject.keyword | Chronic hepatitis B,Hepatitis B Virus-related Hepatocellular carcinoma,Antiviral therapy,Hepatocellular carcinoma,Mortality, | en |
| dc.relation.page | 124 | |
| dc.rights.note | 同意授權(全球公開) | |
| dc.date.accepted | 2015-08-19 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf | 4.51 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。